Deleterious Outcomes after Abrupt Transition from Insulin Glargine to Insulin Detemir in Patients with Type 1 Diabetes Mellitus

Author： Kabadi Udaya M.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.28, Iss.11, 2008-01, pp. : 697-701

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Insulin detemir weighs in against insulin glargine in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1545, 2006-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

In patients with type 1 diabetes mellitus, the pharmacokinetic profile of insulin detemir is similar across age ranges

By  

Inpharma, Vol. 1, Iss. 1413, 2003-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Insulin glargine: advantages in type 1 diabetes mellitus in children and adolescents

By  

Inpharma, Vol. 1, Iss. 1360, 2002-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Insulin detemir is an effective long-acting human insulin analogue for the treatment of type 1 and 2 diabetes mellitus

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 9, 2005-09 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Insulin Detemir: A Review of its Use in the Management of Type 1 and 2 Diabetes Mellitus

By Therese M. Chapman   Caroline M. Perry  

Drugs, Vol. 64, Iss. 22, 2004-01 ,pp. : 2577-2595

Adis International

Access to resources Recommend Favorite